De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Pacira BioSciences Beheer
Beheer criteriumcontroles 2/4
De CEO Pacira BioSciences' is Frank Lee, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.018% van de aandelen van het bedrijf, ter waarde $ 124.40K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.1 jaar.
Belangrijke informatie
Frank Lee
Algemeen directeur
n/a
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | less than a year |
Eigendom CEO | 0.02% |
Management gemiddelde ambtstermijn | 2.8yrs |
Gemiddelde ambtstermijn bestuur | 5.1yrs |
Recente managementupdates
Recent updates
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14CEO
Frank Lee (56 yo)
less than a year
Tenure
Mr. Frank D. Lee served as an Independent Director at Bolt Biotherapeutics, Inc. since November 2021 until September 2024. He is Independent Director of Bausch Health Companies Inc. from May 14, 2024. He i...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chief Operating Officer | 2.4yrs | US$1.53m | 0.027% $ 194.7k | |
Chief Administrative Officer & Secretary | 10yrs | US$1.60m | 0% $ 0 | |
Advisor | less than a year | US$6.88m | 0.51% $ 3.8m | |
Chief Medical Officer | 3.3yrs | US$1.59m | 0.028% $ 206.3k | |
CEO & Director | less than a year | geen gegevens | 0.018% $ 131.3k | |
Interim CFO | 12.6yrs | US$288.82k | 0.0046% $ 34.0k | |
Head of Investor Relations | no data | geen gegevens | geen gegevens | |
Chief Legal & Compliance Officer | 2.8yrs | US$2.05m | 0.028% $ 204.6k | |
Vice President of Human Resources | 9.3yrs | geen gegevens | geen gegevens | |
Chief Manufacturing Officer | 1.5yrs | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PCRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO & Director | less than a year | geen gegevens | 0.018% $ 131.3k | |
Independent Director | 13.3yrs | US$364.01k | 0.027% $ 195.8k | |
Chairman of the Board | 13.3yrs | US$390.51k | 0.016% $ 119.1k | |
Independent Director | 17.8yrs | geen gegevens | geen gegevens | |
Independent Director | 11.3yrs | US$373.01k | 0.043% $ 312.6k | |
Independent Director | 5.1yrs | US$325.01k | 0.011% $ 83.6k | |
Independent Director | less than a year | US$427.86k | 0% $ 0 | |
Independent Director | less than a year | US$426.45k | 0.011% $ 78.1k | |
Independent Director | less than a year | US$427.16k | 0% $ 0 | |
Independent Director | 7.3yrs | US$349.01k | 0.020% $ 146.9k | |
Independent Director | less than a year | US$427.16k | 0.0043% $ 31.8k |
5.1yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PCRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).